K111335

Tosoh Bioscience, Inc.

DEC - 1 2011

# 510(k) Summary

# ST AIA-PACK ACTH

# Date:

August 16, 2011

# Submitter:

Tosoh Bioscience, Inc 3600 Gantz Road Grove City, OH 43123

Contact Person:

Judith K. Ogden   
Director, New Business & Technical Development   
6000 Shoreline Ct., Ste. 101   
South San Francisco, CA 94080   
Phone: 650-636-8112   
Fax: 650-636-8113   
Email: Judy.Ogden@tosoh.com

# Device Name:

ST AIA-PACK ACTH

Classification:

Class II   
CKG   
Clinical Chemistry 21 CFR 862.1025

# Device Name:

# ST AIA-PACK ACTH Calibrator Set

Classification

Class II   
JIT   
Clinical Chemistry 21 CFR 862.1150

# Device Name:

AIA-PACK ACTH Control Set

Classification

Class I   
JJX   
Clinical Chemistry 21 CFR 862.1660

Predicate Device:

k 060585 Roche Diagnostics Elecsys ACTH Immunoassay Elecsys ACTH CalSet

# 510(k) Summary

# ST AIA-PACK ACTH

According to the requirements of 21 CFR 807.92, the following information provides sufficient detail to understand the basis for a determination of substantial equivalence.

# Device Description:

The ST AIA-PACK ACTH is a two-site immunoenzymometric assay which is performed entirely in the ST AIA-PACK ACTH test cups. ACTH present in the test sample is bound with antiACTH goat polyclonal antibody immobilized on magnetic beads and enzyme-labeled anti-ACTH goat polyclonal antibody. The magnetic beads are washed to remove unbound enzyme-labeled anti-ACTH goat polyclonal antibody and are then incubated with a fluorogenic substrate, 4- methylumbelliferyl phosphate (4MUP). The enzyme alkaline phosphatase causes oxidation of 4MUP to 4MU. 4MU is excited at $3 6 5 ~ \mathrm { { n m } }$ and comes to ground state at $4 4 8 \ \mathsf { n m }$ releasing florescent energy. The amount of florescent energy is measured by the detector.

The amount of enzyme-labeled anti-ACTH goat polyclonal antibody that binds to the beads is directly proportional to the ACTH concentration in the test sample. A standard curve is constructed, and unknown sample concentrations are calculated using this curve.

The following products are required to use the ST AIA-PACK ACTH

P/N 025221:

# ST AIA-PACK ACTH Calibrator Set ST AIA-PACK ACTH Sample Diluting Solution AIA-PACK ACTH Control Set

P/N 025321   
P/N 025521   
P/N 025421

Device Intended Use:

ST AIA-PACK ACTH is designed for IN VITRO DIAGNOSTIC USE ONLY for the quantitative measurement of adrenocorticotropic hormone (ACTH) in human EDTA plasma. Measurements of ACTH are useful in the differential diagnosis and treatment of certain disorders of the adrenal glands such as Cushing's syndrome, adrenocortical insufficiency, and the ectopic ACTH syndrome.

ST AIA-PACK ACTH Calibrator Set is intended for IN VITRO DIAGNOSTIC USE ONLY for the calibration of the ST AIA-PACK ACTH assay on Tosoh AIA Systems Analyzers.

The AIA-PACK ACTH Control Set is intended for IN VITRO DIAGNOSTIC USE ONLY for performing quality control procedures with the ST AIA-PACK ACTH Assay.

Tosoh Bioscience, Inc.

# Substantial Equivalence:

# Comparison between the Tosoh ST AIA-PACK ACTH and the Roche Diagnostics Elecsys ACTH Immunoassay

Similarities:

<table><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Device</td><td rowspan=1 colspan=1>Predicate</td></tr><tr><td rowspan=1 colspan=1>nmlow</td><td rowspan=1 colspan=1>ST AIA-PACK ACTH</td><td rowspan=1 colspan=1>Elecsys ACTH</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>ST AIA-PACK ACTH isdesigned for IN VITRODIAGNOSTIC USE ONLYfor the quantitativemeasurement ofAdrenocorticotropic hormone(ACTH) in human EDTAplasma on Tosoh AIA SystemAnalyzers.</td><td rowspan=1 colspan=1>Immunoassay for the in vitroquantitative determination ofadrenocorticotropic hormone(ACTH) in human EDTAplasma. Theelectrochemiluminescenceimmunoassay &quot;ECLIA&quot; isintended for use on the RocheElecsys 1010/2010 andMODULAR ANALYTICSE170 (Elecsys module)immunoassay analyzers.</td></tr><tr><td rowspan=1 colspan=1>Intended Use Calibrators</td><td rowspan=1 colspan=1>ST AIA-PACK ACTHCalibrator Set is intended forIN VITRO DIAGNOSTICUSE ONLY for the calibrationof the ST AIA-PACK ACTHassay on Tosoh AIA SystemsAnalyzers.</td><td rowspan=1 colspan=1>Elecsys ACTH CalSet is usedfor calibrating the quantitativeElecsys ACTH assay on theElecsys immunoassayanalyzers.</td></tr><tr><td rowspan=1 colspan=1>Intended Use Controls</td><td rowspan=1 colspan=1>The AIA-PACK ACTHCONTROL SET is intendedfor IN VITRO DIAGNOSTICUSE ONLY for performingquality control procedureswith the ST AIA-PACKACTH Assay.</td><td rowspan=1 colspan=1>Elecsys PreciControl ACTH isused for quality control of theElecsys ACTH immunoassayon the Elecsys immunoassayanalyzers.</td></tr><tr><td rowspan=1 colspan=1>Indications for Use</td><td rowspan=1 colspan=1>Plasma ACTH measurementsare useful in the differentialdiagnosis of pituitaryCushing&#x27;s disease (ACTHhypersecretion),adrenocortical insufficiency(Addisons disease), pituitarytumors (e.g. Nelson&#x27;ssyndrome), hypopituitarismwith ACTH deficiency andectopic ACTH syndrome.</td><td rowspan=1 colspan=1>ACTH measurements are usedin the differential diagnosisand treatment of certaindisorders of the adrenal glandssuch as Cushings syndrome,adrenocortical insufficiency,and ectopic ACTH syndrome.</td></tr><tr><td rowspan=1 colspan=1>Assay Protocol</td><td rowspan=1 colspan=1>Sandwich assay</td><td rowspan=1 colspan=1>Sandwich Assay</td></tr><tr><td rowspan=1 colspan=1>Sample Type</td><td rowspan=1 colspan=1>Human EDTA Plasma</td><td rowspan=1 colspan=1>Human EDTA Plasma</td></tr><tr><td rowspan=1 colspan=1>Assay Low</td><td rowspan=1 colspan=1>2.0 pg/mL</td><td rowspan=1 colspan=1>1.0 pg/mL</td></tr></table>

Tosoh Bioscience, Inc.

<table><tr><td rowspan=1 colspan=1>Assay High</td><td rowspan=1 colspan=1>2000 pg/mL</td><td rowspan=1 colspan=1>2000 pg/mL</td></tr><tr><td rowspan=1 colspan=1>Reference Range</td><td rowspan=1 colspan=1>7.4-64.3 pg/mL</td><td rowspan=1 colspan=1>7.2-63.3 pg/mL</td></tr><tr><td rowspan=1 colspan=1>Hook Effect</td><td rowspan=1 colspan=1>No high dose hook effect up to1,000,000 pg/mL</td><td rowspan=1 colspan=1>No high dose hook effect up to1,000,000 pg/mL</td></tr><tr><td rowspan=1 colspan=1>Control level</td><td rowspan=1 colspan=1>Two levels of control;lyophilized</td><td rowspan=1 colspan=1>Two levels of control;lyophilized</td></tr></table>

# Differences:

<table><tr><td rowspan=1 colspan=1>Item         20</td><td rowspan=1 colspan=1>DevicerWhM</td><td rowspan=1 colspan=1>Predicate S1R6</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>ST AIA-PACK ACTH</td><td rowspan=1 colspan=1>Elecsys ACTH</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Detection Protocol</td><td rowspan=1 colspan=1>Fluorescence</td><td rowspan=1 colspan=1>Electrochemiluminescent</td></tr><tr><td rowspan=1 colspan=1>Calibrator</td><td rowspan=1 colspan=1>ST AIA-PACK Calibrator Set6-Point</td><td rowspan=1 colspan=1>ACTH CalSet 2-Point</td></tr><tr><td rowspan=1 colspan=1>Calibration Interval</td><td rowspan=1 colspan=1>90 days when using same testcup lot</td><td rowspan=1 colspan=1>3-28 Days depending onanalyzer and storageconditions</td></tr><tr><td rowspan=1 colspan=1>Calibration Verification</td><td rowspan=1 colspan=1>6-Point Calibration does notrequire calibration verificationmaterial</td><td rowspan=1 colspan=1>3 levels ACTH CalCheck</td></tr><tr><td rowspan=1 colspan=1>Traceability / Standardization</td><td rowspan=1 colspan=1>ACTH (Human, 1-39)Bachem AG: code. H-1160;gravimetric preparation</td><td rowspan=1 colspan=1>Standardized gravimetricallywith synthetic ACTHproduced by Roche</td></tr><tr><td rowspan=1 colspan=1>Base Matrix (Control &amp;Calibrator)</td><td rowspan=1 colspan=1>MOPSO Buffer with 5%Bovine Serum Albumin</td><td rowspan=1 colspan=1>Equine serum</td></tr><tr><td rowspan=1 colspan=1>Reconstituted stability</td><td rowspan=1 colspan=1>Up to 7 days when stored at 2- 8° C when not in use.</td><td rowspan=1 colspan=1>Up to 3 hours at 20 - 25° C;- 20° C one month.</td></tr></table>

Tosoh Bioscience, Inc.

# Precision:

The precision study was developed with reference to the CLSI protocol entitled: Evaluation of Precision Performance of Quantitative Measurement Methods (EP5-A2).

The precision study for the ST AIA-PACK ACTH assay was evaluated utilizing three AIA-2000 analyzers and 3 different lots of reagents. Precision was assessed by assaying three levels of unaltered EDTA plasma specimens. Estimates of total and within-run precision were obtained from measurements of 2 replicates in a single run, 2 times a day for 20 non-consecutive days. This equaled to a total of 40 runs and 80 determinants.

Within Run Precision:

Total Precision:   

<table><tr><td rowspan=2 colspan=1>Specimen</td><td rowspan=1 colspan=3>Reagent Set # 1</td><td rowspan=1 colspan=3>Reagent Set # 2</td><td rowspan=1 colspan=3>Reagent Set # 3</td></tr><tr><td rowspan=1 colspan=1>Mean(pg/mL)</td><td rowspan=1 colspan=1>PooledSD</td><td rowspan=1 colspan=1>CV%</td><td rowspan=1 colspan=1>Mean(pg/mL)</td><td rowspan=1 colspan=1>PooledSD</td><td rowspan=1 colspan=1>CV%</td><td rowspan=1 colspan=1>Mean(pg/mL)</td><td rowspan=1 colspan=1>PooledSD</td><td rowspan=1 colspan=1>CV%</td></tr><tr><td rowspan=1 colspan=1>EDTAPlasma-A</td><td rowspan=1 colspan=1>37.8</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>3.1</td><td rowspan=1 colspan=1>44.3</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>2.8</td><td rowspan=1 colspan=1>40.9</td><td rowspan=1 colspan=1>0.89</td><td rowspan=1 colspan=1>2.2</td></tr><tr><td rowspan=1 colspan=1>EDTAPlasma-B</td><td rowspan=1 colspan=1>223.7</td><td rowspan=1 colspan=1>4.8</td><td rowspan=1 colspan=1>2.1</td><td rowspan=1 colspan=1>244.6</td><td rowspan=1 colspan=1>5.1</td><td rowspan=1 colspan=1>2.1</td><td rowspan=1 colspan=1>230.0</td><td rowspan=1 colspan=1>5.3</td><td rowspan=1 colspan=1>2.3</td></tr><tr><td rowspan=1 colspan=1>EDTAPlasma-C</td><td rowspan=1 colspan=1>709.2</td><td rowspan=1 colspan=1>10.9</td><td rowspan=1 colspan=1>1.5</td><td rowspan=1 colspan=1>740.4</td><td rowspan=1 colspan=1>15.6</td><td rowspan=1 colspan=1>2.1</td><td rowspan=1 colspan=1>719.1</td><td rowspan=1 colspan=1>15.5</td><td rowspan=1 colspan=1>2.2</td></tr></table>

<table><tr><td rowspan=2 colspan=1>Specimen</td><td rowspan=1 colspan=3>Reagent Set # 1</td><td rowspan=1 colspan=3>Reagent Set # 2</td><td rowspan=1 colspan=3>Reagent Set # 3</td></tr><tr><td rowspan=1 colspan=1>Mean(pg/mL)</td><td rowspan=1 colspan=1>PooledSD</td><td rowspan=1 colspan=1>CV%</td><td rowspan=1 colspan=1>Mean(pg/mL)</td><td rowspan=1 colspan=1>PooledSD</td><td rowspan=1 colspan=1>CV%</td><td rowspan=1 colspan=1>Mean(pg/mL)</td><td rowspan=1 colspan=1>PooledSD</td><td rowspan=1 colspan=1>CV%</td></tr><tr><td rowspan=1 colspan=1>EDTAPlasma-A</td><td rowspan=1 colspan=1>37.8</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>3.3</td><td rowspan=1 colspan=1>44.3</td><td rowspan=1 colspan=1>1.9</td><td rowspan=1 colspan=1>4.2</td><td rowspan=1 colspan=1>40.9</td><td rowspan=1 colspan=1>1.03</td><td rowspan=1 colspan=1>I2.5</td></tr><tr><td rowspan=1 colspan=1>EDTAPlasma-B</td><td rowspan=1 colspan=1>223.7</td><td rowspan=1 colspan=1>5.7</td><td rowspan=1 colspan=1>2.5</td><td rowspan=1 colspan=1>244.6</td><td rowspan=1 colspan=1>9.3</td><td rowspan=1 colspan=1>3.8</td><td rowspan=1 colspan=1>230.0</td><td rowspan=1 colspan=1>6.4</td><td rowspan=1 colspan=1>2.8</td></tr><tr><td rowspan=1 colspan=1>EDTAPlasma-C</td><td rowspan=1 colspan=1>709.2</td><td rowspan=1 colspan=1>15.6</td><td rowspan=1 colspan=1>2.2</td><td rowspan=1 colspan=1>740.4</td><td rowspan=1 colspan=1>25.1</td><td rowspan=1 colspan=1>3.4</td><td rowspan=1 colspan=1>719.1</td><td rowspan=1 colspan=1>15.9</td><td rowspan=1 colspan=1>2.2</td></tr></table>

Tosoh Bioscience, Inc.

# Linearity:

The ery suy as deveope w enheS pro nt: va e Linearity of Quantitative Measurement Procedures (EP6-A).

The repeatability $C V \%$ met the criterion of $< 1 = 1 0 \%$ Therefore, the ST AIA-PACK ACTH has been demonstrated to be linear from 2.0 to $2 { , } 0 0 0 ~ \mathsf { p g / m L }$ .

# Correlation:

The methods comparison study was conducted with reference to the CLSl protocol entitled: Method Comparison and Bias Estimation Using Patient Samples; Approved Guideline (EP9-A2).

A total of 160 EDTA plasma specimens (154 unaltered and 6 altered specimens) were assayed in singleton utilizing the ST AIA-PACK ACTH assay on the AIA-2000 analyzer and the Roche Elecsys-ACTH on the MODULAR ANALYTICS E170 (Elecsys module) analyzer. A combination of fresh and frozen specimens was utilized for this study. Six of the 160 specimens were mixed using two or more specimens and altered.

<table><tr><td rowspan=1 colspan=3>Regression Analysis</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Deming</td><td rowspan=1 colspan=1>Regular</td></tr><tr><td rowspan=1 colspan=1>Slope:</td><td rowspan=1 colspan=1>1.10 (1.075 to 1.116)</td><td rowspan=1 colspan=1>1.09 (1.067 to 1.107)</td></tr><tr><td rowspan=1 colspan=1>Intercept:</td><td rowspan=1 colspan=1>-0.84 (-8.921 to 7.234)</td><td rowspan=1 colspan=1>0.76 (-7.305 to 8.817)</td></tr><tr><td rowspan=1 colspan=2>95% Confidence Intervals are shown in parentheses</td><td rowspan=1 colspan=1>cYanmaGentaYlelow</td></tr><tr><td rowspan=1 colspan=1>Corr Coef (R):</td><td rowspan=1 colspan=2>0.993</td></tr><tr><td rowspan=1 colspan=1>Bias: (all samples)</td><td rowspan=1 colspan=2>17.8 pg/mL</td></tr><tr><td rowspan=1 colspan=1>Points (Plotted/Total):</td><td rowspan=1 colspan=2>160/160</td></tr><tr><td rowspan=1 colspan=1>Result Ranges:</td><td rowspan=1 colspan=2>3.8 to 1986 pg/mL</td></tr></table>

The mean bias at the medical decision point (between 7.4 and $6 4 . 3 \mathrm { p g / m L ) }$ is 4.87 ${ \mathfrak { p g } } / { \mathfrak { m L } }$ .The bias at $7 . 7 3 ~ { \mathsf { p g / m L } }$ is $- 0 . 8 7 \ p \mathrm { g / m L }$ .The bias at $6 4 . 9 7 ~ \mathrm { p g / m L }$ is -17.93 ${ \mathfrak { p g } } / { \mathfrak { m L } }$ .

# Limit of Detection (LoD) and Limit of Quantitation (LoQ):

The LoB and LoD for ST AIA-PACK ACTH was determination was based on guidance from CLSI Protocol EP17-A. While the calculated LoQ is $1 . 2 p \mathrm { g / m L }$ , the assay low claim is 2.0 ${ \mathsf { p g / m L } }$ .This value is a conservative claim in the event of lot-to-lot variability.

The LoB was determined to be $0 . 5 ~ { \mathsf { p g / m L } }$ . The LoD was determined to be $0 . 7 ~ \mathrm { p g / m L }$ . The LoQ was determined to be $1 . 2 p \mathsf { g / m L }$

Tosoh Bioscience, Inc.

# Interference:

The criterion for recovery was set at $1 0 0 + 1 - 1 0 \%$ . If a specimen recovered within $1 0 0 + 1 - 1 0 \%$ ,it was considered as no interference from the particular substance.

1. Added hemoglobin (up to $4 4 0 ~ \mathrm { m g / d L }$ )did not interfere with the assay.   
2. Conjugated bilirubin (up to $1 9 \mathrm { m g / d L ) }$ and free bilirubin (up to $1 7 { \mathrm { m g / d L } }$ did not   
interfere with the assay.   
3. Lipemia, as indicated by added triglyceride (up to $1 , 6 0 0 \mathrm { m g / d L } ,$ , did not interfere   
4. Ascorbic acid (up to $2 0 \mathrm { m g / d L ) }$ did not interfere with the assay.   
5. EDTA·2K (up to $7 \mathrm { m g / m L }$ did not interfere with the assay.   
6. Protein, as indicated by human albumin concentrations (up to ${ \mathfrak { H } } . 0 \ { \mathfrak { g } } / { \mathrm { d L } } ) ,$ , did not interfere   
with the assay.   
7. Rheumatoid factor did not interfere with ACTH assay up to $5 0 0 ~ \mathrm { I U / m L }$ .   
8. Heparin (up to $5 0 \mathrm { U } / \mathrm { m L }$ does not interfere with the assay.   
9. Acetominaphen (up to $2 0 \mathrm { m g / L }$ ) does not interfere with the assay.   
10. Acetylsalicylic acid (up to $3 0 0 \mathrm { m g / L } $ ) does not interfere with the assay.   
11. Ampicillin (up to $2 0 0 ~ \mathrm { { m g / L } }$ ) does not interfere with the assay.   
12. Ibuprofen (up to $5 0 m \mathbf { g } / \mathbf { L }$ ) does not interfere with the assay.   
13. Theophylline (up to $1 0 \ m g / \mathrm { L }$ does not interfere with the assay.

# Specificity:

The recovery of ACTH should be within $9 0 - 1 1 0 \%$ .

<table><tr><td rowspan=2 colspan=1>ACTHFragment</td><td rowspan=2 colspan=1>ACTHfragmentconc.[pg/mL]</td><td rowspan=1 colspan=3>Measured ACTH conc.[pg/mL]</td><td rowspan=2 colspan=1>Difference(measured- original)</td><td rowspan=2 colspan=1>ACTHRecovery[%]</td><td rowspan=2 colspan=1>% Cross-reactivity</td></tr><tr><td rowspan=1 colspan=1>Value-1</td><td rowspan=1 colspan=1>Value-2</td><td rowspan=1 colspan=1>Average</td></tr><tr><td rowspan=1 colspan=1>(Control)</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>55.1</td><td rowspan=1 colspan=1>53.6</td><td rowspan=1 colspan=1>54.3</td><td rowspan=1 colspan=1>--*</td><td rowspan=1 colspan=1>---</td><td rowspan=1 colspan=1>-</td></tr><tr><td rowspan=3 colspan=1>ACTH 1-10</td><td rowspan=1 colspan=1>500</td><td rowspan=1 colspan=1>54.4</td><td rowspan=1 colspan=1>54.2</td><td rowspan=1 colspan=1>54.3</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>-0.01%</td></tr><tr><td rowspan=1 colspan=1>5,000</td><td rowspan=1 colspan=1>55.0</td><td rowspan=1 colspan=1>54.4</td><td rowspan=1 colspan=1>54.7</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>101%</td><td rowspan=1 colspan=1>0.01%</td></tr><tr><td rowspan=1 colspan=1>100,000</td><td rowspan=1 colspan=1>55.3</td><td rowspan=1 colspan=1>56.1</td><td rowspan=1 colspan=1>55.7</td><td rowspan=1 colspan=1>1.3</td><td rowspan=1 colspan=1>102%</td><td rowspan=1 colspan=1>0.00%</td></tr><tr><td rowspan=3 colspan=1>ACTH 11-24</td><td rowspan=1 colspan=1>500</td><td rowspan=1 colspan=1>53.5</td><td rowspan=1 colspan=1>53.4</td><td rowspan=1 colspan=1>53.4</td><td rowspan=1 colspan=1>-0.9</td><td rowspan=1 colspan=1>98%</td><td rowspan=1 colspan=1>-0.18%</td></tr><tr><td rowspan=1 colspan=1>5,000</td><td rowspan=1 colspan=1>54.1</td><td rowspan=1 colspan=1>53.0</td><td rowspan=1 colspan=1>53.6</td><td rowspan=1 colspan=1>-0.8</td><td rowspan=1 colspan=1>99%</td><td rowspan=1 colspan=1>-0.02%</td></tr><tr><td rowspan=1 colspan=1>100,000</td><td rowspan=1 colspan=1>53.8</td><td rowspan=1 colspan=1>53.8</td><td rowspan=1 colspan=1>53.8</td><td rowspan=1 colspan=1>-0.5</td><td rowspan=1 colspan=1>99%</td><td rowspan=1 colspan=1>0.00%</td></tr><tr><td rowspan=3 colspan=1>Beta-MSH</td><td rowspan=1 colspan=1>500</td><td rowspan=1 colspan=1>53.7</td><td rowspan=1 colspan=1>54.0</td><td rowspan=1 colspan=1>53.8</td><td rowspan=1 colspan=1>-0.5</td><td rowspan=1 colspan=1>99%</td><td rowspan=1 colspan=1>-0.10%</td></tr><tr><td rowspan=1 colspan=1>5,000</td><td rowspan=1 colspan=1>54.1</td><td rowspan=1 colspan=1>54.9</td><td rowspan=1 colspan=1>54.5</td><td rowspan=1 colspan=1>0.2</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>0.00%</td></tr><tr><td rowspan=1 colspan=1>100,000</td><td rowspan=1 colspan=1>51.1</td><td rowspan=1 colspan=1>52.1</td><td rowspan=1 colspan=1>51.6</td><td rowspan=1 colspan=1>-2.8</td><td rowspan=1 colspan=1>95%</td><td rowspan=1 colspan=1>0.00%</td></tr><tr><td rowspan=3 colspan=1>Beta-Endorphin</td><td rowspan=1 colspan=1>500</td><td rowspan=1 colspan=1>53.1</td><td rowspan=1 colspan=1>53.0</td><td rowspan=1 colspan=1>53.0</td><td rowspan=1 colspan=1>-1.3</td><td rowspan=1 colspan=1>98%</td><td rowspan=1 colspan=1>-0.26%</td></tr><tr><td rowspan=1 colspan=1>5,000</td><td rowspan=1 colspan=1>54.9</td><td rowspan=1 colspan=1>53.5</td><td rowspan=1 colspan=1>54.2</td><td rowspan=1 colspan=1>-0.1</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>0.00%</td></tr><tr><td rowspan=1 colspan=1>100,000</td><td rowspan=1 colspan=1>53.1</td><td rowspan=1 colspan=1>52.5</td><td rowspan=1 colspan=1>52.8</td><td rowspan=1 colspan=1>-1.5</td><td rowspan=1 colspan=1>97%</td><td rowspan=1 colspan=1>0.00%</td></tr></table>

ACTH 1-10, 11-24, beta-MSH and beta-Endorphin do not interfere the assay up to 100,000 pg/mL.

Tosoh Bioscience, Inc.

ACTH recovery was less than $90 \%$ in the presence of ACTH 1-17, 1-24, 18-39, alpha-MSH $( > 5 , 0 0 0 _ { \tt P E } / \mathrm { m L } )$ or ACTH ${ 2 2 - 3 9 \left( > 1 0 0 , 0 0 0 \mathrm { p g / m L } \right) }$ . These fragments may negatively affect the ACTH assay. It is likely that these fragments bind to either the antibodies on beads or the enzyme-labeled antibodies. Therefore, if these fragments were contained excessively in the test sample, lower values may be reported.

Standards:   

<table><tr><td rowspan=1 colspan=1>Number</td><td rowspan=1 colspan=1>FDARecognitionNumber</td><td rowspan=1 colspan=1>RevisionDate</td><td rowspan=1 colspan=1>Title</td></tr><tr><td rowspan=1 colspan=1>C28-A3</td><td rowspan=1 colspan=1>7-202</td><td rowspan=1 colspan=1>09/08/2009</td><td rowspan=1 colspan=1>How to Define and Determine Reference Intervalsin the Clinical Laboratory-Third Edition</td></tr><tr><td rowspan=1 colspan=1>EP5-A2</td><td rowspan=1 colspan=1>7-110</td><td rowspan=1 colspan=1>10/31/2005</td><td rowspan=1 colspan=1>Evaluation of Precision Performance ofQuantitative Measurement Methods: ApprovedGuideline- Second Edition</td></tr><tr><td rowspan=1 colspan=1>EP6-A</td><td rowspan=1 colspan=1>7-193</td><td rowspan=1 colspan=1>03/18/2009</td><td rowspan=1 colspan=1>Evaluation of the Linearity of QuantitativeMeasurement Procedures; A Statistical Approach;Approved Guideline</td></tr><tr><td rowspan=1 colspan=1>EP9-A2</td><td rowspan=1 colspan=1>7-92</td><td rowspan=1 colspan=1>03/08/2004</td><td rowspan=1 colspan=1>Method Comparison and Bias Estimation UsingPatient Samples; Approved Guideline-SecondEdition</td></tr><tr><td rowspan=1 colspan=1>EP17-A</td><td rowspan=1 colspan=1>7-194</td><td rowspan=1 colspan=1>03/18/2009</td><td rowspan=1 colspan=1>Protocols for Determination of Limits of Detectionand Limits of Quantitation: Approved Guideline</td></tr></table>

# Control Value Assignment:

The control value assignments are established on 2 analyzers with 2 lots of ST AIAPACK ACTH. Both levels of control are assayed in 5 replicates, and the Mean and $\% C V$ are calculated. This mean serves as the Grand Mean for the Control Assigned Value Range Validation. The range is established $a s + 1 - 2 0 \%$ of the grand mean. The validation acceptance criteria is $+ / - 1 0 \%$ of the grand mean. The end users are instructed to establish their own range.

# Conclusion:

The Tosoh Bioscience, Inc. ST AIA-PACK ACTH is substantially equivalent to the Roche Diagnostics Elecsys ACTH Immunoassay (k)060585 for the in vitro diagnostic use only for the quantitative measurement of ACTH in human EDTA plasma, on Tosoh AIA System Analyzer. Since ACTH is controlled by factors affecting the hypothalamic, pituitary and adrenal glands, the determination of ACTH level is useful in clinical investigation for diseases of these glands.

TOSOH BIOSCIENCE, INC   
c/o Judith Ogden   
6000 Shoreline Court   
Suite 101   
South San Francisco, CA 94080

Re: k111335 Trade Name: ST AIA-PACK ACTH, ST AIA-PACK ACTH Calibrator Set, AIA-PACK ACTH Control Set Regulation Number: 21 CFR 862.1025 Regulation Name: Adrenocorticotropic hormone (ACTH) test system Regulatory Class: Class II Product Codes: CKG, JIT, JJX Dated: November 15, 2011 Received: November 16, 2011

Dear Ms. Ogden:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA inay publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).

Page 2

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 796-5450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometric's (OSB's) Division of Postmarket Surveillance at (301) 796-5760. For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/Medical   
Devices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance...

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-5680 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm

Sincerely yours,

2

Coupney H. Lias, Ph.D.   
Director   
Division of Chemistry and Toxicology Devices Office of In Vitro Diagnostic Device   
Evaluation and Safety   
Center for Devices and Radiological Health

# Indications for Use

510(k) Number (if known):

k111335

Device Name:

ST AIA-PACK ACTH

Indication For Use:

ST AIA-PACK ACTH is designed for IN VITRO DIAGNOSTIC USE ONLY for the quantitative measurement of adrenocorticotropic hormone (ACTH) in human EDTA plasma. Measurements of ACTH are used in the differential diagnosis and treatment of certain disorders of the adrenal glands such as Cushing's syndrome, adrenocortical insufficiency, and the ectopic ACTH syndrome.

Device Name:

# ST AIA-PACK ACTH Calibrator Set

Indication For Use:

ST AIA-PACK ACTH Calibrator Set is designed for IN VITRO DIAGNOSTIC USE ONLY for the calibration of the ST AlA-PACK ACTH assay on Tosoh AIA System Analyzers :

# Device Name:

ST AIA-PACK ACTH Control Set

Indication For Use:

ST AIA-PACK ACTH Control Set is designed for IN VITRO DIAGNOSTIC USE ONLY for performing quality control procedures with the ST AIA-PACK ACTH assay on Tosoh AIA System Analyzers

Prescription Use _ (21 CFR Part 801 Subpart D)

And/Or

Over the Counter Use (21 CFR Part 801 Subpart C)